| pubmed-article:9305915 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9305915 | lifeskim:mentions | umls-concept:C0206131 | lld:lifeskim |
| pubmed-article:9305915 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:9305915 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:9305915 | lifeskim:mentions | umls-concept:C0443199 | lld:lifeskim |
| pubmed-article:9305915 | lifeskim:mentions | umls-concept:C0851285 | lld:lifeskim |
| pubmed-article:9305915 | pubmed:issue | 39 | lld:pubmed |
| pubmed-article:9305915 | pubmed:dateCreated | 1997-10-23 | lld:pubmed |
| pubmed-article:9305915 | pubmed:abstractText | Modulation of beta-adrenoreceptor expression by tumor necrosis factor-alpha (TNF-alpha) was investigated in murine 3T3-F442A adipocytes. TNF-alpha treatment of mature adipocytes decreased beta3-adrenoreceptor mRNA content in a time- and concentration-dependent manner, with a 8.5-fold decrease observed after a 6-h exposure to 300 pM TNF-alpha. beta1-Adrenoreceptor mRNA abundance was slightly decreased by TNF-alpha treatment, while beta2-adrenoreceptor mRNA levels were potently induced (6-fold increase at 6 h). (-)-[125I]Iodocyanopindolol saturation and competition binding experiments indicated that TNF-alpha induced a 2-fold decrease in beta3-adrenoreceptor number, a nonsignificant reduction in beta1-subtype population, and a approximately 4.5-fold increase in beta2-adrenoreceptor density. This correlated with a lower EC50 value measured for epinephrine in stimulating adenylyl cyclase, whereas the EC50 value for norepinephrine increased. Nuclear run-on assays on isolated nuclei and mRNA stability measurements showed that TNF-alpha increased both beta2-adrenoreceptor gene transcription and beta2-adrenoreceptor mRNA half-life, while beta1- and beta3-adrenoreceptor gene expression was modulated only at the transcriptional level by the cytokine. These findings demonstrate a differential modulation by TNF-alpha of the three beta-adrenoreceptor subtypes in adipocytes, which may contribute to metabolic disorders induced by the cytokine in the adipocyte. | lld:pubmed |
| pubmed-article:9305915 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9305915 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9305915 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9305915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9305915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9305915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9305915 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9305915 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:9305915 | pubmed:issn | 0021-9258 | lld:pubmed |
| pubmed-article:9305915 | pubmed:author | pubmed-author:PairaultJJ | lld:pubmed |
| pubmed-article:9305915 | pubmed:author | pubmed-author:Chambaut-Guér... | lld:pubmed |
| pubmed-article:9305915 | pubmed:author | pubmed-author:HaeseJ BJB | lld:pubmed |
| pubmed-article:9305915 | pubmed:author | pubmed-author:CourtalonAA | lld:pubmed |
| pubmed-article:9305915 | pubmed:author | pubmed-author:FèveBB | lld:pubmed |
| pubmed-article:9305915 | pubmed:author | pubmed-author:GauthereauXX | lld:pubmed |
| pubmed-article:9305915 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9305915 | pubmed:day | 26 | lld:pubmed |
| pubmed-article:9305915 | pubmed:volume | 272 | lld:pubmed |
| pubmed-article:9305915 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9305915 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9305915 | pubmed:pagination | 24514-21 | lld:pubmed |
| pubmed-article:9305915 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:meshHeading | pubmed-meshheading:9305915-... | lld:pubmed |
| pubmed-article:9305915 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9305915 | pubmed:articleTitle | Differential regulation by tumor necrosis factor-alpha of beta1-, beta2-, and beta3-adrenoreceptor gene expression in 3T3-F442A adipocytes. | lld:pubmed |
| pubmed-article:9305915 | pubmed:affiliation | INSERM Unité 282, Hôpital Henri Mondor, 94010 Créteil, France. | lld:pubmed |
| pubmed-article:9305915 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9305915 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:11554 | entrezgene:pubmed | pubmed-article:9305915 | lld:entrezgene |
| entrez-gene:11555 | entrezgene:pubmed | pubmed-article:9305915 | lld:entrezgene |
| entrez-gene:11556 | entrezgene:pubmed | pubmed-article:9305915 | lld:entrezgene |
| entrez-gene:21926 | entrezgene:pubmed | pubmed-article:9305915 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9305915 | lld:pubmed |
